A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

Recruiting

Phase 1

ASP5834 with PanitumumabA Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

Sponsor:

Astellas Pharma Inc

Code:

NCT07094204

Conditions

Solid Tumor

Non-Small-Cell Lung Cancer

Pancreatic Ductal Adenocarcinoma

Colorectal Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

ASP5834

panitumumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-03-14. This information was provided to ClinicalTrials.gov by Astellas Pharma Inc on 2026-02-23.